{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-002558","form_type":"8-K","ticker":"OMER","cik":"0001285819","company_name":"OMEROS CORP","filed_at":"2022-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.782739+00:00","generated_at":"2026-06-27T02:48:58.799301+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Omeros Q4 net income $280.6M including OMIDRIA gain; adjusted loss $0.37/share","bullets":["Net income Q4 2021 $280.6M ($4.48/share) includes $184.6M non-cash gain from OMIDRIA royalty capitalization and $126M cash proceeds from sale.","Adjusted Q4 net loss excluding OMIDRIA divestiture would have been $23.0M ($0.37/share) vs Q3 loss $22.7M ($0.36/share).","Completed sale of OMIDRIA to Rayner Surgical on Dec 23, 2021 for $126M cash; Omeros retains 50% US royalty until $200M milestone then 30% thereafter.","Received FDA Complete Response Letter for narsoplimab BLA in TA-TMA in Oct 2021; held Type A meeting in Feb 2022, awaiting FDA response.","Cash and short-term investments $157.3M at Dec 31, 2021 plus $38.2M accounts receivable expected to be collected in Q1 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-002558","json":"https://secwatch.observer/filing/0001558370-22-002558.json","markdown":"https://secwatch.observer/filing/0001558370-22-002558.md","text":"https://secwatch.observer/filing/0001558370-22-002558.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285819/000155837022002558/0001558370-22-002558-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285819/000155837022002558/omer-20220301x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T02:48:58.799301+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}